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Aminoacylation of tRNA is the cellular process to provide aminoacyl donors for the 
ribosome synthesis of polypeptides. New research highlights an unexpected structural 
overlap between enzymes involved in this process and those involved in the 
biosynthesis of cyclodipeptides, an important class of bioactive molecules.  
 
The canonical role of tRNA in ribosomal protein synthesis begins with aminoacylation catalyzed 
by aminoacyl-tRNA synthetases (aaRSs). Each aaRS activates its cognate amino acid with ATP 
and esterifies the intermediate aminoacyl-AMP (aa-AMP) to the 3’ terminal ribose of tRNA to 
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form the product aminoacyl-tRNA (aa-tRNA), which enters the ribosome according to the tRNA 
anticodon. Although the ribosome machinery is highly efficient, thanks to protein factors that 
ensure rapid capture of aa-tRNA to support protein synthesis, recent work has shown that some 
aa-tRNAs can escape capture and instead participate in peptide synthesis outside the 
ribosome. For example, cyclodipeptide synthases (CDPSs) hijack aa-tRNAs to make 
cyclodipeptides1 (Fig.1a), but how they accomplish this task was unknown. One page xx of this 
issue2, Blanchard and colleagues report the crystal structure of one of these enzymes, revealing 
a surprising homology to aaRSs with interesting new insights into the mechanism of making 
cyclodipeptides from aa-tRNAs.  
 
Cyclodipeptides and their derivatives are important diketopiperazine compounds with diverse 
biodefense activities; hence an understanding of their biosynthesis is expected to impact human 
health. While most cyclodipeptides are synthesized by the large non-ribosome peptide 
synthetases in microorganisms, albonoursin biosynthesis relies on a small enzyme, the AlbC 
protein of Streptomyces noursei, to synthesize the cyclodipeptide precursor cyclo(L-Phe-L-Leu) 
(cFL)3. The AlbC activity is unorthodox1; it does not use free L-phenylalanine and L-leucine as 
substrates, but instead requires the pre-charged Phe-tRNAPhe and Leu-tRNALeu. This unusual 
activity explains the lack of an ATP-binding motif in AlbC and relates it to proteins of two other 
families that use aa-tRNAs to make peptides: aa-tRNA protein transferases4 and aminoacyl 
transferases5. An in silico search has identified several AlbC homologues1, with subsequent 
biochemical experiments confirming their CDPS activity1. One of these is Rv2275 from 
Mycobacterium tuberculosis, which uses two molecules of Tyr-tRNATyr to synthesize cyclo(L-
Tyr-L-Tyr) (cYY) as an intermediate in mycocyclosin biosynthesis.   
 
Although a recent protein sequence profile analysis has suggested that CDPSs may be related 
to the aa-tRNA-synthesizing aaRSs6, the low homology between the two families of enzymes 
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precluded any speculation as to the structural features of CDPSs. Thus, the crystal structure of 
Rv2275 provided by Blanchard and colleagues is a surprise: the protein is structurally most 
closely related to TyrRS and TrpRS, the class Ic members of aaRSs. The aaRSs have been 
divided into two major classes according to their ATP-binding motifs: class I enzymes use the 
common protein fold known as the Rossmann fold to bind ATP for generating the intermediate 
aa-AMP and converting it to aa-tRNA, whereas class II enzymes bind ATP in an antiparallel 
core of β-strands. Unlike the monomeric structure of all other class I enzymes, class Ic enzymes 
are distinguished by a dimeric structure with the two active sites interdigitated at the dimer 
interface. Rv2275 is also a dimer, possessing similarly arranged active sites while containing 
notable structural rearrangements that would block ATP binding (Fig.1b). Importantly, of the 
many conserved CDPS-signature residues that cluster near a putative amino acid-binding 
pocket of Rv2275 is Ser88, whose spatial position is a determinant of the ATP-independent 
active site and is relevant to catalysis. Indeed, the alanine substitution of Ser88 completely 
abolishes the enzyme activity and prevents the formation of a crucial reaction intermediate. This 
intermediate, when formed In the wild-type Rv2275 after incubation with [14C]-Tyr-tRNATyr and 
separation of the tRNA, contains the radiolabel and is stable enough to survive even in 
denaturing condition with 5 M urea, suggesting that it is a tyrosinylated covalent enzyme 
complex. These observations form the basis for a proposed mechanism of Rv2275 that may be 
generalizable to other CDPSs.  
 
In the proposed mechanism (Fig.1a), the Ser88 hydroxyl performs nucleophilic attack on the 
carbonyl ester of the first aa1-tRNA1, leading to the formation of the covalent enzyme-aa1 
intermediate and the release of the deacylated tRNA1. Structural data suggest that the active 
site should rearrange to accommodate the entry of a second aa2-tRNA2, upon which the α-
amino group of the tRNA-bound aa2 would attack the enzyme-bound aa1 to generate the tRNA-
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bound dipeptide aa1-aa2. Following a second nucleophilic attack by the α-amino group of aa1 on 
the carbonyl ester of aa2 is the formation of the product cyclodipeptide and the release of tRNA2. 
Mutational analysis implicates the involvement of a general base in the active site (the CDPS-
signature residue E233 of Rv2275) that would accelerate proton abstraction of the α-amino 
group of aa2-tRNA2 to promote nucleophilic attack and would also assist in the protonation of 
the deacylated tRNA2 to facilitate product release.  
 
The proposed mechanism highlights two remarkable features of making cyclodipeptides on 
tRNA. One is the sequential use of aa-tRNAs as the donors of already activated amino acids, 
thus affording CDPSs with a small structure (without the amino-acid activation domain) to 
catalyze a complex reaction. The second is the covalent trapping of the first amino acid on 
CDPSs while arranging the second aa-tRNA for the chemistry step. This covalent strategy may 
be necessary to compete for the cellular pools of aa-tRNAs, which after synthesis on aaRSs are 
typically captured by elongation factor EF-Tu for rapid delivery to the ribosome. However, even 
with the first amino acid stabilized, the competition for the second aa-tRNA is formidably more 
challenging because the covalent mechanism is no longer invoked. Intriguingly, their structural 
homology to class Ic aaRSs suggests that CDPSs should bind aa-tRNA favorably, because 
class I aaRSs generally exhibit preferentially high affinities to the aa-tRNA product7, and 
because the dimeric Ic structure has been suggested to serve as a barrier to prevent direct 
release of aa-tRNA to EF-Tu7. These considerations provide a useful framework to appreciate 
the unexpected structural homology.  
  
The current structure should be a springboard to jump start additional structural work on the 
CDPS enzymes, preferably in complexes with bound substrates. Such structures will help to 
address unresolved questions, pertaining to their selectivity of aa-tRNA, the determinants for the 
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sequential entry of aa-tRNA, and the operational relationship of the two active sites. Together 
with more detailed biochemical analysis, new insights are likely to emerge enabling the design 
of novel cyclodipeptides for medical purposes.  
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Legend to Figure 1: 
(a) Peptide synthesis from aminoacyl-tRNAs. Aminoacylation of a tRNA by an aaRS (blue), 
using an amino acid (aa) and ATP as substrates, generates an aa-tRNA that is typically 
released to GTP-bound EF-Tu (purple) and delivered to the ribosome (grey) for synthesis of a 
new peptide bond on a nascent polypeptide. However, some aa-tRNAs are hijacked by CDPSs 
(green) to make cyclodipeptides, using a covalent trapping strategy that fixes the aa from the 
first aa-tRNA (red) on the enzyme while making a dipeptide with the second aa-tRNA (metallic).  
 
(b) Structural homology of Rv2275 and TyrRS. The active site of Rv2275 contains a putative 
amino acid-binding site (aa site) structurally homologous with the aa site of the class Ic TyrRS, 
but features a “closed” loop conformation (blue) that would block ATP binding as opposed to the 
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“open” loop conformation of the ATP site in TyrRS. Drawn with PyMol based on coordinates of 
Rv2275 (PDB 2X9Q) and TyrRS (PDB 1VBM).  
 
 
 
 
 
 
 
